An ActRIIA fusion protein got FDA approved for PAH treatment

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure.

Three major health care policy issues to watch in 2025

WASHINGTON — Health care did not play a big role in the election that’s sending President Trump back to the White House and giving Republicans

December 16, 2024

ADVANZ PHARMA, Veeva Systems partner for digital operations

The Veeva CRM Suite and Veeva OpenData allow ADVANZ to coordinate more effectively with healthcare professional touchpoints across channels and regions. Credit: National Cancer Institute

June 22, 2023

How has the prevalence of psychological distress in the adult population of England changed since 2020?

Researchers estimated patterns of psychological distress.

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.